rs121918488
Variant summary
Our verdict is Pathogenic. Variant got 19 ACMG points: 19P and 0B. PM1PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000141.5(FGFR2):c.1024T>G(p.Cys342Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 11/18 in silico tools predict a damaging outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. C342F) has been classified as Pathogenic.
Frequency
Consequence
NM_000141.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 19 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FGFR2 | NM_000141.5 | c.1024T>G | p.Cys342Gly | missense_variant | 8/18 | ENST00000358487.10 | NP_000132.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FGFR2 | ENST00000358487.10 | c.1024T>G | p.Cys342Gly | missense_variant | 8/18 | 1 | NM_000141.5 | ENSP00000351276.6 | ||
FGFR2 | ENST00000613048.4 | c.757T>G | p.Cys253Gly | missense_variant | 7/17 | 5 | ENSP00000484154.1 | |||
FGFR2 | ENST00000478859.5 | c.340T>G | p.Cys114Gly | missense_variant | 7/17 | 1 | ENSP00000474011.1 | |||
FGFR2 | ENST00000457416.7 | c.1087+1303T>G | intron_variant | 1 | ENSP00000410294.2 | |||||
FGFR2 | ENST00000369056.5 | c.1087+1303T>G | intron_variant | 1 | ENSP00000358052.1 | |||||
FGFR2 | ENST00000369058.7 | c.1087+1303T>G | intron_variant | 1 | ENSP00000358054.3 | |||||
FGFR2 | ENST00000369061.8 | c.749-2060T>G | intron_variant | 1 | ENSP00000358057.4 | |||||
FGFR2 | ENST00000369059.5 | c.742+1303T>G | intron_variant | 5 | ENSP00000358055.1 | |||||
FGFR2 | ENST00000360144.7 | c.820+1303T>G | intron_variant | 2 | ENSP00000353262.3 | |||||
FGFR2 | ENST00000604236.5 | n.*71T>G | non_coding_transcript_exon_variant | 7/17 | 1 | ENSP00000474109.1 | ||||
FGFR2 | ENST00000604236.5 | n.*71T>G | 3_prime_UTR_variant | 7/17 | 1 | ENSP00000474109.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
FGFR2-related craniosynostosis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 10, 2024 | This sequence change replaces cysteine, which is neutral and slightly polar, with glycine, which is neutral and non-polar, at codon 342 of the FGFR2 protein (p.Cys342Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Pfeiffer syndrome (PMID: 10394936, 31754721). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 374818). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt FGFR2 protein function with a positive predictive value of 95%. This variant disrupts the p.Cy342 amino acid residue in FGFR2. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8644708, 9586546, 12884424, 12884434, 24127277, 25271085, 26362256). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. - |
Pfeiffer syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | Sep 17, 2016 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 02, 2020 | Variants altering the two critical cysteine residues 278 and 342 account for 60% of all pathogenic variants observed in (Robin et al., 2011); Cys342 variants have a gain-of-function effect; they cause abnormal dimerization and dimer structure resulting in FGFR2 activation, aberrant cell growth and blocking of cellular differentiation (Mansukhani et al., 2000); experimental mice models for C342Y have demonstrated significant defects in skull development (Holmes et al., 2018); Not observed in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 31754721, 10394936, 23754559) - |
FGFR2-related syndromic and non-syndromic craniosynostoses Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Feb 19, 2019 | The FGFR2 c.1024T>G (p.Cys342Gly) variant is a missense variant occurring at an established mutational hotspot within the FGFR2 gene. The p.Cys342Gly variant has been reported in one study, in which it is reported in a heterozygous state in two unrelated individuals with clinical diagnoses of Pfeiffer syndrome. In one family the p.Cys342Gly variant was shown to be absent from both parents, consistent with a de novo occurrence (Cornejo-Roldan et al. 1999). Additionally, at least six variants resulting in different missense variants at the Cys342 residue have been reported in literature in individuals with clinical diagnoses including Pfeiffer, Crouzon and Jackson-Weiss syndromes (Park et al. 1995; Cornejo-Roldan et al. 1999; Lajeunie et al. 2006; Li et al. 2016). The p.Cys342Gly variant was absent from 100 control subjects and is not found in the Genome Aggregation Database. In vitro analysis in NIH 3T3 cell found variants that alter the Cys342 residue are associated with increased tyrosine kinase activity and aberrant generation of disulfide-bonded dimers (Galvin et al. 1996). The Cys342 residue is highly conserved and located in the Ig-III domain (Li et al. 2016). Based on the collective evidence, the p.Cys342Gly variant is classified as pathogenic for FGFR2-related syndromic and non-syndromic craniosynostoses. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at